| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
2-Iodomelatonin targets melatonin receptor 1 (MT1) as a potent agonist with a Ki of 28 pM. Its selectivity for MT1 is more than 5 times that of MT2. It acts as a potent agonist at the melatonin receptor, mimicking the effects of the endogenous hormone melatonin.
|
|---|---|
| ln Vitro |
2-iodomelatonin (0-7.5 μM; 18 hours) reduces the growth of Rip2 expression in stress-mutant htt ST14A cells and has the same protective effects as melatonin [2]. It also prevents cell death in mutant htt ST14A cells.
In vitro, 2-Iodomelatonin (0-7.5 µM; 18 hours) reduces the growth of Rip2 expression in stress-mutant htt ST14A cells and has the same protective effects as melatonin. It also prevents cell death in mutant htt ST14A cells. It is a potent agonist of melatonin receptor 1 (MT1) with a Ki of 28 pM and an EC₅₀ value of 11 pM. |
| ln Vivo |
In vivo, 2-Iodomelatonin may be utilized to identify, characterize and localize melatonin binding sites in the brain and peripheral tissues. Its potent and selective agonism at MT1 makes it a valuable tool for studying the role of melatonin receptors in circadian rhythms, sleep, and other physiological processes. Detailed in vivo pharmacokinetic and efficacy studies are available.
|
| Enzyme Assay |
In vitro receptor binding assays for 2-Iodomelatonin typically involve radioligand binding studies to determine its affinity for melatonin receptors. The receptor is incubated with increasing concentrations of the compound and a fixed concentration of a radiolabeled melatonin ligand. Bound and free radioligand are separated, and radioactivity is measured. Ki values are calculated from competition binding curves. Functional assays measure its ability to activate MT1-mediated signaling.
|
| Cell Assay |
Cell viability assay [2]
Cell Types: mutant htt ST14A Cell Tested Concentrations: 0 μM; 1 μM; 5 μM; 7.5 μM Incubation Duration: 18 hrs (hours) Experimental Results: Inhibition of mutant htt ST14A cell death. For in vitro cell-based assays, cells expressing the MT1 receptor are cultured and treated with 2-Iodomelatonin. Receptor activation is measured by quantifying the inhibition of forskolin-stimulated cAMP accumulation or other downstream signaling pathways. Its protective effects can be assessed in cell models of stress or neurodegeneration, such as mutant htt ST14A cells. Cell viability is assessed by standard assays. |
| Animal Protocol |
In vivo animal studies with 2-Iodomelatonin are typically conducted to study melatonin receptor function. The compound can be administered to rodents to study its effects on circadian rhythms, sleep, or neuroprotection. Receptor occupancy and localization can be assessed using radiolabeled 2-[¹²⁵I]-iodomelatonin in autoradiography studies. Brain and peripheral tissues are collected for analysis.
|
| ADME/Pharmacokinetics |
2-Iodomelatonin (CAS: 93515-00-5) has a molecular weight of 358.17 g/mol and a molecular formula of C₁₃H₁₅IN₂O₂. Appearance: Off-white to yellow solid powder. LogP: 2.85. Storage: Powder -20°C 3 years, 4°C 2 years; In solvent -80°C 6 months, -20°C 1 month. Solubility: DMF 30 mg/mL, DMSO ~30 mg/mL, Ethanol ~20 mg/mL.
|
| Toxicity/Toxicokinetics |
2-Iodomelatonin is a research compound and is not approved for human therapeutic use. In preclinical studies, it has shown a manageable safety profile. As a potent MT1 agonist, it may have effects on circadian rhythms and sleep. Standard laboratory safety precautions should be followed when handling the compound.
|
| References |
|
| Additional Infomation |
N-[2-(2-iodo-5-methoxy-1H-indol-3-yl)ethyl]acetamide is a member of the acetamide class of compounds.
2-Iodomelatonin is a potent agonist of melatonin receptor 1 (MT1) with a Ki of 28 pM and exhibits over 5-fold selectivity for MT1 compared to MT2. It can be utilized to identify, characterize and localize melatonin binding sites. It is not FDA-approved and is intended for research use only. |
| Molecular Formula |
C13H15N2O2I
|
|---|---|
| Molecular Weight |
358.1744
|
| Exact Mass |
358.018
|
| CAS # |
93515-00-5
|
| PubChem CID |
115348
|
| Appearance |
Off-white to yellow solid powder
|
| Density |
1.63g/cm3
|
| Boiling Point |
574.5ºC at 760mmHg
|
| Flash Point |
301.3ºC
|
| Index of Refraction |
1.654
|
| LogP |
2.85
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
18
|
| Complexity |
301
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
FJDDSMSDZHURBJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H15IN2O2/c1-8(17)15-6-5-10-11-7-9(18-2)3-4-12(11)16-13(10)14/h3-4,7,16H,5-6H2,1-2H3,(H,15,17)
|
| Chemical Name |
N-[2-(2-iodo-5-methoxy-1H-indol-3-yl)ethyl]acetamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMF : 30 mg/mL (~83.76 mM)
DMSO : ~30 mg/mL (~83.76 mM) Ethanol : ~20 mg/mL (~55.84 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.98 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7920 mL | 13.9599 mL | 27.9197 mL | |
| 5 mM | 0.5584 mL | 2.7920 mL | 5.5839 mL | |
| 10 mM | 0.2792 mL | 1.3960 mL | 2.7920 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
